Comparative in vitro and in vivo antimicrobial activities of sitafloxacin, gatifloxacin and moxifloxacin against Mycobacterium avium

International Journal of Antimicrobial Agents

Volumn 37, Issue 4, 2011, Pages 296-301

  Sano, Chiaki ^a   Tatano, Yutaka ^a   Shimizu, Toshiaki ^a,b   Yamabe, Seiko ^a   Sato, Katsumasa ^c   Tomioka, Haruaki ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^b YASUDA WOMEN'S UNIVERSITY   (Japan)

^c KOBE WOMEN'S UNIVERSITY   (Japan)

Author keywords

Gatifloxacin; Moxifloxacin; Mycobacterium avium; Sitafloxacin; Therapeutic activity

Indexed keywords

CLARITHROMYCIN; ETHAMBUTOL; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; SITAFLOXACIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; ATYPICAL MYCOBACTERIOSIS; BACTERIAL LOAD; BACTERICIDAL ACTIVITY; BACTERIUM MUTANT; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG; MACROPHAGE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM AVIUM; NONHUMAN; PRIORITY JOURNAL; SPLEEN;

ANIMALS; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; FLUOROQUINOLONES; HUMANS; MICE; MICE, INBRED C3H; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM AVIUM; QUINOLINES;

EID: 79952817985     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.12.014     Document Type: Article

References (22)

1. Tomioka H. Present status and future prospects of chemotherapeutics for intractable infections due to Mycobacterium avium complex. Curr Drug Discov Technol 2004;1:255-68.
2. Heifets L. Clarithromycin against Mycobacterium avium complex infection. Tuber Lung Dis 1996;77:19-26. (Pubitemid 26066605)
3. de Lalla F, Maserati R, Scarpellini P, Marone P, Nicolin R, Caccamo F, et al. Clarithromycin-ciprofloxacin-amikacin for therapy of Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS. Antimicrob Agents Chemother 1992;36:1567-9.
4. Alangaden GJ, Lerner SA. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Clin Infect Dis 1997;25:1213-21. (Pubitemid 27513211)
5. Bermudez LE, Inderlied CB, Kolonoski P, Wu M, Barbara-Burnham L, Young LS. Activities of Bay Y 3118, levofloxacin, and ofloxacin alone or in combination with ethambutol against Mycobacterium avium complex in vitro, in human macrophages, and in beige mice. Antimicrob Agents Chemother 1996;40:546-51. (Pubitemid 26071520)
6. Bermudez LE, Inderlied CB, Kolonoski P, Petrofsky M, Aralar P, Wu M, et al. Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium. Antimicrob Agents Chemother 2001;45:217-22. (Pubitemid 32039118)
7. Bermudez LE, Kolonoski P, Seitz LE, Petrofsky M, Reynolds R, Wu M, et al. SRI-286, a thiosemicarbazole, in combination with mefloquine and moxifloxacin for treatment of murine Mycobacterium avium complex disease. Antimicrob Agents Chemother 2004;48:3556-8. (Pubitemid 39129359)
8. Tomioka H, Sato K, Akaki T, Kajitani H, Kawahara S, Sakatani M. Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Antimicrob Agents Chemother 1999;43:3001-4.
9. Fung-Tomc J, Minassian B, Kolek B, Washo T, Huczko E, Bonner D. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin. J Antimicrob Chemother 2000;45:437-46.
10. Tomioka H, Sano C, Sato K, Shimizu T. Antimicrobial activities of clarithromycin, gatifloxacin and sitafloxacin, in combination with various antimycobacterial drugs against extracellular and intramacrophage Mycobacterium avium complex. Int J Antimicrob Agents 2002;19:139-45. (Pubitemid 34163301)
11. Tomioka H, Saito H, Sato K, Yoneyama T. Therapeutic efficacy of liposome-encapsulated kanamycin against Mycobacterium intracellulare infection induced in mice. Am Rev Respir Dis 1991;144:575-9.
12. Sato K, Akaki T, Tomioka H. Antimicrobial activities of benzoxazinorifamycin KRM-1648, clarithromycin and levofloxacin against intracellular Mycobacterium avium complex phagocytosed by murine peritoneal macrophages. J Antimicrob Chemother 1998;41:77-83. (Pubitemid 28064253)
13. Tomioka H, Sato K, Kajitani H, Akaki T, Shishido S. Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Antimicrob Agents Chemother 2000;44:283-6. (Pubitemid 30060720)
14. Nakashima M, Uematsu T, Kosuge K, Umemura K, Hakusui H, Tanaka M. Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers. Antimicrob Agents Chemother 1995;39:170-4.
15. Rodríguez JC, Cebrián L, López M, Ruiz M, Jiménez I, Royo G. Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis. J Antimicrob Chemother 2004;53:441-4. (Pubitemid 38380240)
16. Bermudez LE, Kolonoski P, Petrofsky M, Wu M, Inderlied CB, Young LS. Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease. J Infect Dis 2003;187:1977-80. (Pubitemid 36724499)
17. Lounis N, Bentoucha A, Truffot-Pernot C, Ji B, O'Brien RJ, Vernon A, et al. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 2001;45:3482-6. (Pubitemid 33107866)
18. Cynamon MH, Sklaney M. Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis. Antimicrob Agents Chemother 2003;47:2442-4. (Pubitemid 36919442)
19. Tomioka H. Current status of some antituberculosis drugs and the development ofnewantituberculous agents with special reference to their in vitro and in vivo antimicrobial activities. Curr Pharm Des 2006;12:4047-70. (Pubitemid 44669760)
20. Gosling RD, Uiso LO, Sam NE, Bongard E, Kanduma EG, Nyindo M, et al. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 2003;168:1342-5. (Pubitemid 37487329)
21. Torriani FJ, Behling CA, McCutchan JA, Haubrich RH, Havlir DV. Disseminated Mycobacterium avium complex: correlation between blood and tissue burden. J Infect Dis 1996;173:942-9. (Pubitemid 26001171)
22. Kohno Y, Ohno H, Miyazaki Y, Higashiyama Y, Yanagihara K, Hirakata Y, et al. In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. Antimicrob Agents Chemother 2007;51:4071-6.